• Genovax completes the recruitment of the patients for the Phase I/II clinical study for GX301

    Genovax, a start up company based at the BioIndustry Park Silvano Fumero in Ivrea (Turin) developing vaccines for autoimmune diseases and cancer, recently has announced that the recruitment of the planned 10 patients has been completed for the ongoing Phase I/II clinical study in patients affected by advanced prostate cancer.
    Genovax’ GX301 is a peptides vaccination targeting telomerase, with the aim of stopping cancer cells proliferation. The company received in December 2009 the regulatory approval to start a Phase I/II clinical study in advanced renal and prostate cancers.
    The study started in January 2010 at the Urology Institute of the University of Genova, and is still ongoing. Patients are now in the follow up phase: preliminary results indicate not only an optimal tolerability and safety profile, but also signs of immune system activation and clinical responses.
    Genovax plans to prepare an interim report for EC submission, asking at the same time for the approval of a Phase II study in prostate cancer patients in an early stage of the disease.